Cardamyst (etripamil) is a prescription intranasal therapy indicated for the acute conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
It is a rapid-acting calcium channel blocker that slows conduction through the atrioventricular (AV) node, helping terminate abnormal cardiac electrical activity responsible for PSVT. Designed for self-administration at symptom onset, Cardamyst provides a convenient, non-injectable option for rapid rhythm control outside of emergency settings.
